US/UK/Canada

Share

Contacts

  • Malene Brondberg

    Chief Financial Officer


    1 Brassey Road, Old Potts Way, Shrewsbury SY3 7FA
    +47 22 18 33 01
    +44 7561 431 762
    http://www.nordicnanovector.com
    • Pick a time period -

    Nordic Nanovector ASA: Allocation of restricted stock units (RSUs) to the board of directors

    Oslo, Norway, 2 June 2021 Reference is made to the minutes from Nordic Nanovector ASA's (the "Company") (OSE: NANOV) annual general meeting held on 28 April 2021 in Oslo, Norway (the "AGM"). At the AGM, the shareholders approved the issuance of restricted stock units ("RSUs") to board members who elect to receive all or parts of their remuneration, for the period from the annual general meeting in 2021 to the annual general meeting in 2022, in the form of RSUs.   The RSUs are non-transferable and each RSU give the right and obligation to acquire one share in the Company at a price

    Nordic Nanovector ASA: Results for the First Quarter 2021

    Oslo, Norway, 26 May 2021 Nordic Nanovector ASA (OSE: NANOV) announces its results for the first quarter 2021. A live webcast presentation by Nordic Nanovector’s management team will take place today at 08.30 CEST. A link to the webcast is available on www.nordicnanovector.com. The results report and the presentation are also available on the company’s website in the section: Investors & Media/Reports and Presentation/Interim Reports/2021. A replay of the webcast will be made available at the same location after the event. Peter L. Braun, Chief Executive Officer of Nordic

    Nordic Nanovector ASA: Resultat for første kvartal 2021

    Oslo, 26. mai 2021 Nordic Nanovector ASA (OSE: NANOV) publiserer i dag resultatene for første kvartal 2021. Selskapets ledelse vil presentere resultatene i en direktesendt webcast i dag kl. 08.30. En lenke til webcasten er tilgjengelig på www.nordicnanovector.com. Resultatrapporten og presentasjonen er også tilgjengelig på selskapet nettside under fanen: Investors & Media/Reports and Presentation/Interim Reports/2021. Et opptak av webcasten legges ut på siden i etterkant av presentasjonen. “Nordic Nanovector har gjort viktige fremskritt så langt i 2021. Vi har fått på plass ny

    Nordic Nanovector Announces Update from Archer-1 Phase 1b Trial of Betalutin® in combination with rituximab in 2L Follicular Lymphoma

    Oslo, Norway, 25 May 2021 Nordic Nanovector ASA (OSE: NANOV) announces initial promising data from the Archer-1 Phase 1b trial investigating Betalutin® ([177]Lu lilotomab satetraxetan) in combination with rituximab (RTX) in second-line follicular lymphoma (2L FL). The preliminary results show clinical activity with seven out of seven patients achieving a response, including 5 complete responses and 2 partial responses. All responses are currently ongoing, 5 of them 2 years after Betalutin® administration. Across this patient group, Betalutin® with RTX showed a very good safety

    Nordic Nanovector ASA: Invitation to First Quarter 2021 Results Presentation and Webcast

    Oslo, Norway, 20 May 2021 Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the first quarter 2021 on Wednesday, 26 May 2021. A presentation by Nordic Nanovector’s senior management team will be webcast live the same day at 8:30am CET. The webcast can be accessed from www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page after the event. The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim

    Nordic Nanovector ASA: Annual General Meeting held

    Oslo, Norway, 28 April 2021 The Annual General Meeting of Nordic Nanovector ASA (the "Company") (OSE: NANOV) was held today on 28 April 2021 in Oslo, Norway. All proposals were resolved by the Annual General Meeting as presented in the notice convening the general meeting distributed on 7 April 2021. The complete minutes of the Annual General Meeting are attached to this release, and are available on www.nordicnanovector.com. For further information, please contact:                 IR enquiries Malene Brondberg, CFOCell: +44 7561 431 762Email: ir@nordicnanovector.com

    Nordic Nanovector ASA - Share capital increase registered

    Oslo, Norway, 20 April 2021 Reference is made to the stock exchange announcement on 12 April 2021 regarding the final result of Nordic Nanovector ASA's (OSE: NANOV) (the "Company") the repair offering where 2,699,280 new shares (the "New Shares") were allocated at a subscription price of NOK 22.75 per share /the "Repair Offering"). The share capital increase pertaining to the Repair Offering has now been registered in the Norwegian Register of Business Enterprises (the "NRBE") on 20 April 2021. The Company's share capital has been increased with NOK 539,856 through the issuance of the

    Nordic Nanovector ASA – Final results of the repair offering

    Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN Oslo, Norway, 12 April 2021 Reference is made to the stock exchange announcement from Nordic Nanovector ASA (the "Company") dated 22 March 2021 relating to the repair offering and listing of up to 2,699,280 new shares, each with a nominal value of NOK 0.20 (the "Offer Shares") at

    Nordic Nanovector ASA – Preliminary results of the repair offering

    Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN Oslo, Norway, 9 April 2021 Reference is made to the stock exchange announcement from Nordic Nanovector ASA (the "Company") dated 22 March 2021 relating to the repair offering and listing of up to 2,699,280 new shares, each with a nominal value of NOK 0.20 (the "Offer Shares") at a

    Nordic Nanovector ASA: Notice of Annual General Meeting on 28 April 2021

    Oslo, Norway, 7 April 2021 Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 28 April 2021, at 14:00 hours CEST at Kjelsåsveien 168 B 0884 Oslo. The full notice with appendices and the recommendation from the Nomination Committee are attached. The notice and the documents to which it refers are also available on www.nordicnanovector.com. Shareholders wishing to attend the Annual General Meeting, in person or by proxy, must complete and return the attendance form or power of attorney form attached to the notice to Nordea Bank Abp, Issuer Service,

    Nordic Nanovector ASA Announces Proposed Board Change

    Oslo, Norway, 7 April 2021 Nordic Nanovector ASA (OSE: NANOV) announces that its Nomination Committee has nominated Mrs Solveig Hellebust for election as a Non-executive Director at the Company’s Annual General Meeting on 28 April 2021.  The company also notes that Mrs Hilde Hermansen Steineger, PhD, who has served as a Non-executive Director on the Board of Nordic Nanovector since November 2014 has, due to increased workload, responsibilities and other priorities, decided not to stand for re-election at the upcoming AGM. Mrs Hellebust has 20 years of business experience mainly in

    Nordic Nanovector ASA publishes 2020 Annual Report

    Oslo, Norway, 26 March 2021 On 26 March 2021, the Board of Directors of Nordic Nanovector ASA approved the Company’s financial statements for 2020. The Company’s 2020 Annual Report is attached and available on Nordic Nanovector ASA’s website: www.nordicnanovector.com. For further information, please contact: IR enquiries Malene Brondberg, CFOCell: +44 7561 431 762Email: ir@nordicnanovector.com Media Enquiries Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)Tel: +44 203 926 8535Email: nordicnanovector@citigatedewerogerson.com About Nordic Nanovector:

    Nordic Nanovector ASA – allocation of PSUs

    Oslo, Norway, 26 March 2021 The Board of Directors of Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") has on 26 March 2021 decided to grant 1,070,000 Performance Share Units ("PSUs") to employees in accordance with the authorisation granted at the Annual General Meeting held on 10 June 2020 (the "AGM"). The terms and conditions of the PSUs, which are part of the Company's long-term incentive plan for employees, are described on pages 27-30 in the Company's annual report for 2019. The PSUs are granted without consideration. The PSUs are non-transferable and will vest

    Nordic Nanovector ASA – Commencement of the subscription period in the repair offering

    Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN Oslo, Norway, 25 March 2021 Reference is made to the stock exchange announcement from Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") published on 23 February 2021 regarding the successfully completed private placement raising approximately NOK 361 million in gross

    Nordic Nanovector ASA: Prospectus approved

    Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN Oslo, Norway, 22 March 2021 Reference is made to the stock exchange announcements on 23 February 2021 where Nordic Nanovector ASA (the "Company") announced that the Company had carried out a successful private placement raising gross proceeds of approximately NOK 361 million (the "

    Nordic Nanovector ASA – Resolution to increase the share capital in connection with the repair offering and terms of the repair offering

    Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN Oslo, Norway, 22 March 2021 Reference is made to the stock exchange announcement from Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") published on 23 February 2021 regarding the successfully completed private placement raising approximately NOK 361 million in gross

    Nordic Nanovector ASA: Extraordinary general meeting held

    Oslo, Norway, 22 March 2021 Nordic Nanovector ASA (the "Company") announces that an extraordinary general meeting in the Company was held today at the Company's offices in Kjelsåsveien 168B, 0884 Oslo. The extraordinary meeting approved all items on the agenda, including the authorisation to the Board of Directors to increase the share capital in connection with a potential repair offering as announced on 23 February 2021 and 1 March 2021. The minutes from the extraordinary general meeting are attached and are also available at www.nordicnanovector.com. As previously announced, a

    Nordic Nanovector Appoints Experienced Pharmaceutical Company Leader Peter L. Braun as Chief Executive Officer

    Oslo, Norway, 17 March 2021 Nordic Nanovector ASA (OSE: NANOV) announces the appointment of Peter L. Braun as Chief Executive Officer (CEO). He will take up the position on 6 April 2021 and will be based in the company’s office in Zug, Switzerland. Mr Braun is an experienced and entrepreneurial pharmaceutical leader, with extensive commercialisation experience with innovative oncology products and deep knowledge of pharmaceutical markets worldwide from a career spanning nearly 30 years at Hoffmann-La-Roche (“Roche”). During his career at Roche, Mr Braun led the Lifecycle Management

    Nordic Nanovector ASA: Financial calendar

    Oslo, Norway, 12 March 2021 FINANCIAL YEAR 2020 · 22.03.2021 - Extraordinary General Meeting · 26.03.2021 - Annual Report FINANCIAL YEAR 2021 · 28.04.2021 - Annual General Meeting · 26.05.2021 - Quarterly Report - Q1 · 27.08.2021 - Half-yearly Report · 18.11.2021 - Quarterly Report - Q3 For further information, please contact:                             IR enquiries Malene Brondberg, CFOCell: +44 7561 431 762Email: ir@nordicnanovector.com Media Enquiries Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)Tel: +44 203 926 8535

    Nordic Nanovector to present at Carnegie’s upcoming Nordic Virtual Healthcare Seminar 2021

    Oslo, Norway, 9 March 2021 Nordic Nanovector ASA (OSE: NANOV) announces that its Interim CEO, Dr Lars Nieba will present a corporate overview, via live webcast, and host one-on-one meetings with investors at the Carnegie’s upcoming Nordic Virtual Healthcare Seminar 2021, taking place 9-12 March 2021. Presentations details are as follows: Carnegie Nordic Virtual Healthcare Seminar 2021Date: Friday, 12 March 2021Time: 12:00 (noon) – 12:30 CET The company presentation will be available on Nordic Nanovector’s Investors and Media page at the same time. For further information,

    Nordic Nanovector to present at 11[th] Annual World ADC Europe 2021 Digital

    Oslo, Norway, 8 March 2020 Nordic Nanovector ASA (OSE: NANOV) announces that its Chief Scientific Officer, Jostein Dahle, will give a presentation on 9 March at the 11[th] Annual World ADC Europe 2021 Digital  event (8-11 March 2021) in the Discovery stream discussing the question: Should Payloads be Super-Potent? Presentation details are as follows: Title: Targeting CD37 with Alpha- & Beta-Emitting Radioimmunoconjugates Date/time: Tuesday, 9 March 2021 at 11:40am GMT During his presentation, Dr Dahle with cover the following points: ·

    Nordic Nanovector ASA – Notice of extraordinary general meeting

    Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN Oslo, Norway, 1 March 2021 Reference is made to the stock exchange announcements by Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") on 23 February 2021 regarding the successfully completed private placement of 15,878,122 new shares (the "Private Placement Shares") in

    Nordic Nanovector ASA - Share capital increase registered

    Oslo, Norway, 25 February 2021 Reference is made to the stock exchange announcement on 23 February 2021 regarding the successful completion of Nordic Nanovector ASA's (OSE: NANOV) (the "Company") private placement of new shares (the "Private Placement"). The share capital increase pertaining to the 15,878,122 new shares, each with a nominal value of NOK 0.20, to be issued in the Private Placement (the "New Shares") has been registered in the Norwegian Register of Business Enterprises (the "NRBE") on 25 February 2021, and the Company's share capital has been increased with NOK 3,175,

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe